XP arises from deficiency in the nucleotide excision repair (NER) pathway, which is responsible for identifying and excising bulky DNA adducts generated by UV radiation. The structured packet for this umbrella entity does not certify specific causative genes; causative genes are associated with individual XP complementation group subtypes rather than the umbrella entity. GeneReviews describes XP as following an autosomal recessive mode of inheritance, whereby two pathogenic variants — one on each copy of the relevant NER gene — are required to produce the disorder. This inheritance architecture accounts for the elevated disease prevalence observed in geographically isolated or consanguineous populations, where founder variants are enriched. When NER is disrupted, cells accumulate unrepaired UV-induced DNA lesions that lead to somatic mutations and ultimately malignant transformation in sun-exposed tissues. GeneReviews also documents that cells from individuals with XP exhibit hypersensitivity to DNA damage from environmental mutagens beyond UV, including cigarette smoke, reflecting the generalized impairment in the DNA repair capacity.

According to GeneReviews, XP should be suspected in individuals presenting with specific dermatologic or ocular features. Clinical findings supporting diagnostic suspicion include acute sun sensitivity characterized by severe sunburn with blistering or persistent erythema following minimal UV exposure, marked freckle-like pigmentation on the face appearing before age two years, or skin cancer occurring within the first decade of life. Ocular presentations including photophobia with prominent conjunctival injection or severe keratitis also support the diagnosis, as described by GeneReviews. GeneReviews references published diagnostic criteria proposed by the Japanese Dermatological Association. Laboratory confirmation of XP complementation group assignment involves molecular genetic testing to identify pathogenic variants in the relevant NER gene; the specific gene targeted depends on clinical presentation and family history. GeneReviews describes that cellular UV hypersensitivity can be demonstrated through specialized laboratory studies of DNA repair capacity using cultured cells. Family history of similar UV-sensitive presentations or documented parental consanguinity may raise index of clinical suspicion prior to confirmatory genetic testing.

No FDA-approved treatments are certified in this packet for XP. GeneReviews describes clinical management as primarily oriented toward preventing UV-induced damage and detecting and treating resulting skin and ocular malignancies. According to GeneReviews, premalignant lesions such as actinic keratoses are managed with cryotherapy (freezing with liquid nitrogen). Larger areas of sun-damaged skin are treated with field therapies including topical preparations such as 5-fluorouracil or imiquimod. GeneReviews notes that dermabrasion or therapeutic dermatome shaving is rarely employed to remove more severely damaged superficial epidermal layers, allowing repopulation from relatively UV-shielded follicular cells. Ocular management described by GeneReviews involves regular examination for signs of UV exposure damage. GeneReviews documents that UV exposure from sunlight and from artificial sources — including mercury arc, halogen, and other lamps, which can be unrecognized UV sources in settings such as gymnasiums — is a central consideration in the clinical management of XP. GeneReviews further notes that cells from individuals with XP exhibit hypersensitivity to environmental mutagens including cigarette smoke, a finding documented in the clinical guidelines context. Certified approved treatment options beyond these management approaches are not established in this packet.

The prognosis of XP is substantially shaped by the cumulative UV exposure history, the age at which malignant skin lesions first develop, and whether neurological features are present. GeneReviews documents that freckle-like lesions and xerosis poikiloderma develop universally in affected individuals, with the extent of poikiloderma directly proportional to cumulative UV exposure. The occurrence of skin cancer within the first decade of life, documented by GeneReviews as a characteristic feature, reflects a substantially accelerated malignant course compared to the general population. When neurological manifestations are present, GeneReviews describes these as an additional dimension of disease burden with progressive features. GeneReviews describes a clinical surveillance framework involving dermatologic examination every three to twelve months depending on disease severity, and ophthalmologic examination at least every six months. The overall prognosis for XP depends significantly on the effectiveness of UV protection strategies implemented over the lifespan and the frequency and thoroughness of surveillance for early malignant lesions.

One clinical trial is registered for this condition in this packet. NCT05484570, titled 'Natural History Study for DNA Repair Disorders,' is currently recruiting at the University of Minnesota. This study does not list a phase designation and is oriented toward characterizing the natural history of DNA repair disorders including xeroderma pigmentosum. Natural history studies of this type generate longitudinal data on disease course, clinical variability, and outcome measures that serve as the foundation for future interventional trial design. GeneReviews notes that ClinicalTrials.gov in the United States and the EU Clinical Trials Register in Europe serve as resources for identifying active studies for XP, and acknowledges that there may not be specific clinical trials for this disorder at all times. The nine recognized complementation group subtypes within the XP umbrella mean that research efforts may be distributed across multiple subtype-specific studies not captured in this umbrella-level trial registry.